On September 9, 2020 Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, reported that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 3:00 pm ET (Press release, Viracta Therapeutics, SEP 9, 2020, https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-hc-wainwright-22nd-annual-global-investment-conference-301125916.html [SID1234564892]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 9, 2020 EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported that management will be presenting at the HC Wainwright Virtual 22nd Annual Global Investment Conference, which is being held September 14-15, 2020 (Press release, EDAP TMS, SEP 9, 2020, View Source [SID1234564835]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details
Date: Tuesday, September 15
Time: 10:30am EDT
Webcast: View Source

The webcast will be archived and available for replay for a period of 90 days.

On September 9, 2020 Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, reported that Tom Civik, Chief Executive Officer of Five Prime Therapeutics, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer of Five Prime Therapeutics, will participate in a fireside chat at the 2020 Wells Fargo Virtual Healthcare Conference on Thursday, September 10th at 9:00am Pacific Time / 12:00pm Eastern Time (Press release, Five Prime Therapeutics, SEP 9, 2020, View Source [SID1234564861]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will be webcast and may be accessed from the "Events & Presentations" section of the Company’s website at: View Source Five Prime will maintain an archived replay of the webcast on its website for approximately 30 days after the conference.

On September 9, 2020 Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostics designed to provide physicians with clinically actionable information to improve the patient outcomes, reported that President and CEO Michael Nall will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 3:30 p.m. Eastern time (12:30 p.m. Pacific time) (Press release, Biocept, SEP 9, 2020, View Source [SID1234564894]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live presentation can be accessed here and will be archived on the Investor Relations section of the Biocept website.

On September 9, 2020 Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, reported that the Company plans to participate in several upcoming events (Press release, Onconova, SEP 9, 2020, View Source [SID1234564836]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Marcus Evans Healthcare Investment Webinar
Participation on panel titled "Exploring ESG Investment Opportunities in Healthcare amidst COVID-19" on Thursday, September 10 at 1:00 PM ET

H.C. Wainwright 22nd Annual Global Investment Conference
Company presentation on Monday, September 14 at 1:30 PM ET
Webcast information: View Source

2nd Annual RAS-Targeted Drug Development Conference
Company presentation titled "Rigosertib as a Unique Small Molecule RAS Antagonist: Scientific & Clinical Studies" on Wednesday, September 16 at 11:30 AM ET and panel discussion at 12:50 PM ET